Introduction – Addressing Core RNA Drug Delivery, Formulation Development, and GMP Manufacturing Needs
For biopharmaceutical companies developing RNA-based therapeutics (mRNA vaccines (COVID-19), mRNA cancer immunotherapies, siRNA (small interfering RNA) gene silencing drugs (Patisiran (Onpattro), Inclisiran (Leqvio)), and pDNA (plasmid DNA) gene therapies), the effective delivery of nucleic acids to target cells remains the primary challenge. Naked RNA/DNA is unstable (degraded by RNases/DNases in blood), does not enter cells efficiently (negative charge repels cell membrane), and can trigger innate immune responses (TLR activation). Lipid nanoparticles (LNPs) – nanoscale (50-200 nm) lipid vesicles composed of ionizable cationic lipids, phospholipids, cholesterol, and PEG-lipids – directly resolve these delivery challenges. LNPs encapsulate and protect RNA/DNA from degradation, facilitate cellular uptake (endocytosis), and promote endosomal escape (ionizable lipids become cationic at low pH, destabilize endosomal membrane). Lipid Nanoparticles (LNPs) CDMO services – contract development and manufacturing organizations providing LNP formulation development, process scale-up, GMP manufacturing (clinical and commercial batches), and analytical characterization – support the rapidly growing RNA therapeutics pipeline. These services include: lipid synthesis (ionizable lipids, helper lipids, PEG-lipids), liposome preparation (microfluidics, T-junction, ethanol injection), encapsulation (mRNA, siRNA, pDNA), particle size and polydispersity index (PDI) optimization, encapsulation efficiency (%EE), stability studies, and sterile fill-finish. As mRNA vaccines (COVID-19) prove platform potential (Moderna, Pfizer/BioNTech), and RNAi drugs gain approvals, the market for LNP CDMOs is expanding rapidly. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), nucleic acid payload segmentation, and application-specific insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Lipid Nanoparticles (LNPs) CDMO Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Lipid Nanoparticles (LNPs) CDMO Service market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Lipid Nanoparticles (LNPs) CDMO Service was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985496/lipid-nanoparticles–lnps–cdmo-service
Core Keywords (Embedded Throughout)
- Lipid nanoparticles (LNPs) CDMO service
- mRNA-LNP formulation
- siRNA encapsulation
- Ionizable lipid
- GMP manufacturing
Market Segmentation by Payload Type and Therapeutic Application
The Lipid Nanoparticles (LNPs) CDMO service market is segmented below by both nucleic acid cargo (type) and clinical application (application). Understanding this matrix is essential for CDMOs targeting specific RNA modalities and drug development pipelines.
By Type (Payload / Encapsulated Nucleic Acid):
- mRNA-LNP CDMO (messenger RNA vaccines and therapeutics (COVID-19, influenza, RSV, CMV, personalized cancer vaccines (neoantigen); protein replacement therapy (enzyme deficiency). Largest segment due to COVID-19 vaccine success)
- siRNA-LNP CDMO (small interfering RNA for gene silencing (liver diseases (ATTR amyloidosis (Patisiran), PCSK9 (Inclisiran)), hepatitis B, oncology). Smaller payload)
- pDNA-LNP CDMO (plasmid DNA for gene therapy (ex vivo or in vivo). Less common (larger size, less efficient encapsulation)
- Others (antisense oligonucleotides (ASOs), circRNA, saRNA)
By Application:
- Vaccines and Drugs (prophylactic vaccines (infectious diseases); therapeutic vaccines (cancer); protein replacement; gene silencing; gene therapy)
- Diagnostics and Medical Imaging (LNP-encapsulated contrast agents (MRI, PET), diagnostic probes)
- Nanotherapeutics (targeted drug delivery (small molecules, chemotherapeutics) encapsulated in LNPs)
- Others (cosmetics, agriculture)
Industry Stratification: LNP Manufacturing Process
Pre-formulation: lipid synthesis (ionizable lipid (e.g., ALC-0315, SM-102), DSPC, cholesterol, DMG-PEG2000), excipient characterization.
LNP preparation: microfluidics (mixing ethanol-dissolved lipids with aqueous RNA solution in microfluidic mixer) – produces uniform size, high encapsulation efficiency.
Downstream processing: dialysis or tangential flow filtration (TFF) to remove ethanol, buffer exchange.
Sterile filtration (0.22 µm). Fill-finish (vials, pre-filled syringes).
QC testing: particle size (dynamic light scattering, DLS), polydispersity index (PDI), encapsulation efficiency (Ribogreen assay), zeta potential, lipid content (HPLC-CAD), residual ethanol, sterility, endotoxin.
Recent 6-Month Industry Data (September 2025 – February 2026)
- LNP CDMO Market: rapid growth (mRNA vaccines).
- mRNA Beyond COVID (November 2025): Personalized cancer vaccines (Moderna, BioNTech) in Phase II/III.
- Capacity Expansion (December 2025): Lonza (Visp), Catalent (Bloomington) investing in LNP manufacturing.
- Innovation data (Q4 2025): Evonik “EUDRAGIT LNP” – cationic lipid library for siRNA, mRNA; increased encapsulation efficiency (>95%), reduced liver toxicity. Target: RNA therapeutics.
Typical User Case – mRNA Vaccine CDMO (Clinical Batches)
A biotech company developing a personalized neoantigen mRNA vaccine engages LNP CDMO for GMP manufacturing:
Services: lipid synthesis (ionizable lipid), LNP formulation (microfluidics, 10L scale), encapsulation (mRNA), fill-finish.
QC: particle size (80-120 nm), %EE (>90%), sterility.
Result: clinical trial material delivered for Phase I study.
Technical Difficulties and Current Solutions
Despite success, LNP CDMO faces four persistent technical hurdles:
- Low encapsulation efficiency for large mRNA (pDNA). Optimized lipid composition, microfluidic mixing parameters.
- Particle size uniformity (PDI <0.2). Process control, post-formation filtration.
- Stability (LNPs aggregate over time). Lyophilization, optimized lipid composition.
- Ionizable lipid supply chain (complex synthesis). CDMOs offer in-house lipid synthesis.
Exclusive Industry Observation – The LNP CDMO Market by Payload and Indication
Based on QYResearch’s interviews with 69 RNA therapy executives (October 2025 – January 2026), mRNA-LNP dominant (vaccines); siRNA-LNP fast-growing (hepatic diseases).
mRNA – 70% of LNP CDMO revenue.
siRNA – 20%.
For suppliers, key strategy: invest in mRNA-LNP capacity (up to 500L), ionizable lipid manufacturing, analytical characterization (DLS, HPLC), and stability studies.
Complete Market Segmentation (as per original data)
The Lipid Nanoparticles (LNPs) CDMO Service market is segmented as below:
Major Players:
Evonik, Lonza, Rentschler Biopharma, Samsung Biologics, Hanmi Pharmaceutical, Catalent Biologics, FUJIFILM Pharmaceuticals, CordenPharma, ST Pharm, eTheRNA, Esco Aster, Recipharm, Yuantai Biological Technology, GenScript Biotechnology, WuXi Biologics
Segment by Type:
mRNA-LNP CDMO, siRNA-LNP CDMO, pDNA-LNP CDMO, Others
Segment by Application:
Vaccines and Drugs, Diagnostics and Medical Imaging, Nanotherapeutics, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
